Sensorion
Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.
Top Stages
1 past transactions
Koubachi
Acquisition in 2014
Koubachi AG is a Swiss company specializing in interactive plant care solutions, founded in 2009 and headquartered in Zurich. The company offers a range of products designed to assist users in caring for their plants effectively. Its flagship products include Wi-Fi Plant Sensors that measure soil moisture, temperature, and light intensity, providing users with notifications and tailored care advice based on the specific needs of their plants. Koubachi also provides a mobile application for iPhone and a web application that allows users to manage their plant data and adjust sensor settings. The company's mission is to enhance the way individuals interact with their plants, aiming to embed its technology in every household. Koubachi AG operates as a subsidiary of Husqvarna AB.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.